Last Updated on November 25, 2024 by The Health Master
Form 483
Alembic Pharmaceuticals, a prominent player in the pharmaceutical industry, recently faced regulatory scrutiny from the US Food and Drug Administration (USFDA) by means of Form 483.
The USFDA conducted an inspection of Alembic’s Jarod-based solid oral formulation facility from November 14 to 22, 2024.
Following the inspection, the USFDA issued a Form 483 with five procedural observations.
What Does a Form 483 Mean?
A Form 483 is a document issued by the USFDA to a regulated firm detailing objectionable conditions observed during an inspection.
These observations typically highlight deviations from current Good Manufacturing Practice (cGMP) regulations.
Impact on Alembic’s Operations
While the issuance of a Form 483 is not uncommon in the pharmaceutical industry, it can have potential implications for a company’s operations.
The specific impact on Alembic will depend on the nature of the observations and the company’s ability to address them promptly and effectively.
Alembic’s Response
In response to the USFDA’s observations, Alembic has committed to providing a comprehensive response within the stipulated timeframe.
The company will likely undertake corrective and preventive actions to address the identified issues and ensure compliance with USFDA regulations.
Key Takeaways
- Regulatory Scrutiny: Alembic Pharmaceuticals has faced regulatory scrutiny from the USFDA.
- Form 483 Issuance: The USFDA issued a Form 483 with five procedural observations.
- Potential Impact: The specific impact on Alembic’s operations will depend on the nature of the observations and the company’s response.
- Regulatory Compliance: Alembic is committed to addressing the observations and ensuring compliance with USFDA regulations.
-
What is a Form 483?
A Form 483 is a document issued by the USFDA to a regulated firm detailing objectionable conditions observed during an inspection.
-
What are the potential implications of a Form 483?
A Form 483 can lead to various regulatory actions, including warning letters, import alerts etc.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issued Form 483 with 7 observations to Dr Reddy’s
USFDA issued Form 483 with 4 observations to Shilpa Medicare
USFDA concludes inspection at Granules India with zero observations
USFDA inspection concluded at Alembic Pharma with no observation
USFDA issues positive EIR to Alembic for Panelav facility
USFDA issued Form 483 with observation to Torrent Pharma, Pithampur plant
India to ease Regulations for Stem Cell and Gene Therapy product manufacturing
State Demands National Portal to Track Fake Drugs
NPPA recalculates Ceiling Price of Atorvastatin 10mg
Fire explosion at Aurore Pharmaceuticals
Drug recall: Cipla recalls over 1.8k boxes of this drug
USFDA issued Form 483 with 7 observations to Dr Reddy’s
NPPA Revises Ceiling Prices of these Key Drugs
Approval of Anti Cancer drug Nivolumab for new Indication
Trump 2.0 Agenda: A Boon for Indian Pharma Industry?
DGFT Introduces new norm for Clobetasol Propionate: A Boon for Pharma Exporters
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
